Geron announces multiple additions to senior commercial leadership team

Geron (GERN) highlighted multiple additions to its senior commercial leadership team, as it prepares for the potential commercialization in the U.S. market of imetelstat, a first-in-class telomerase inhibitor. Key additions include seasoned professionals with deep operational and launch experience in Trade & Channel Relations, Market Access, Marketing, Medical Affairs and Sales. Peter Avalos, M.B.A., M.S., Vice President, Trade and Channel Relations. Peter Avalos joined Geron in December 2022 from Daiichi Sankyo (DSNKY). Nishan Sengupta, Ph.D., Vice President, Market Access and Pricing. With over 20 years of experience working in the healthcare industry across both the drug and medical device sectors, Nishan Sengupta was a core brand team member for multiple global and U.S. commercial launches, including Imbruvica, Xarelto and Humira. Lorraine Shui, Pharm.D., M.B.A, Vice President, Marketing. Prior to joining Geron in October 2022, Lorraine Shui was the U.S. brand lead for sickle cell marketing at Novartis Pharmaceuticals Corporation. Denise Meyer, B.Pharm., Pharm.D., M.B.A., Vice President, Medical Affairs. Since August 2021, Denise Meyer has served as Geron’s Vice President, Medical Affairs. Scott Hutson, Vice President, Sales. With over 20 years of experience in commercial organizations across various oncology areas, including hematology, solid tumors and immuno-oncology, Scott Hutson has led and participated in numerous commercial launches in the U.S. for many successful blockbuster drugs, including Procrit, Zytiga, Xtandi, Tagrisso, Imfinizi and Enhertu.